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Abstract
Ribonucleotide reductase is a rate-limiting enzyme in DNA synthesis and is composed of two different proteins, R1 and
R2. The R2 protein appears to be rate-limiting for enzyme activity in proliferating cells, and it is phosphorylated by p34cdc2
and CDK2, mediators of cell cycle transition events. A sequence in the R2 protein at serine-20 matches a consensus sequence
for p34cdc2 and CDK2 kinases. We tested the hypothesis that the serine-20 residue was the major p34cdc2 kinase site of
phosphorylation. Three peptides were synthesized (from Asp-13 to Ala-28) that contained either the wild type amino acid
sequence (Asp-Gln-Gln-Gln-Leu-Gln-Leu-Ser-Pro-Leu-Lys-Arg-Leu-Thr-Leu-Ala, serine peptide) or a mutation, in which
the serine residue was replaced with an alanine residue (alanine peptide) or a threonine residue (threonine peptide). Only the
serine peptide and threonine peptide were phosphorylated by p34cdc2 kinase. In two-dimensional phosphopeptide mapping
experiments of serine peptide and Asp-N endoproteinase digested R2 protein, peptide co-migration patterns suggested that
the synthetic phosphopeptide containing serine-20 was identical to the major Asp-N digested R2 phosphopeptide. To further
test the hypothesis that serine-20 is the primary phosphorylated residue on R2 protein, three recombinant R2 proteins (R2-
Thr, R2-Asp and R2-Ala) were generated by site-directed mutagenesis, in which the serine-20 residue was replaced with
threonine, aspartic acid or alanine residues. Wild type R2 and threonine-substituted R2 proteins (R2-Thr) were
phosphorylated by p34cdc2 kinase, whereas under the same experimental conditions, R2-Asp and R2-Ala phosphorylation
was not detected. Furthermore, the phosphorylated amino acid residue in the R2-Thr protein was determined to be
phosphothreonine. Therefore, by replacing a serine-20 residue with a threonine, the phosphorylated amino acid in R2 protein
was changed to a phosphothreonine. In total, these results firmly establish that a major p34cdc2 phosphorylation site on the
ribonucleotide reductase R2 protein occurs near the N-terminal end at serine-20, which is found within the sequence Ser-Pro-
Leu-Lys-Arg-Leu. Comparison of ribonucleotide reductase activities between wild type and mutated forms of the R2
proteins suggested that mutation at serine-20 did not significantly affect enzyme activity. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
In proliferating mammalian cells, a network of
regulatory enzymes coordinates the timing and exe-
cution of the major transitions of the cell cycle, in-
cluding the initiation of DNA synthesis [1,2]. Mod-
i¢cations in the activities of these regulatory enzymes
can accompany and play important roles in mecha-
nisms of malignant progression [3]. The synthesis of
DNA requires a continuous and balanced supply of
the four deoxyribonucleoside triphosphates that are
derived from the direct reduction of the 2P-carbon
atom on the ribose moiety of ribonucleotides [4].
Since the enzyme ribonucleotide reductase is solely
responsible for this crucial reaction in all living or-
ganisms, it occupies a key rate-limiting position in
the synthesis and repair of DNA, and in cell prolif-
eration [4,5]. The active enzyme is composed of two
di¡erent protein components called R1 and R2, and
as would be expected for such an important enzyme,
its activity is strictly regulated by a very complex
mechanism [4^9]. Alterations in ribonucleotide re-
ductase are associated with major changes in the bio-
logical properties of cells, relevant, for example, to
mechanisms of tumor promotion, response to growth
factors, and sensitivity to chemotherapeutic com-
pounds [4,10]. Recently we have also demonstrated
that deregulation of R2 expression can act as a novel
tumor progressor determinant, capable of cooperat-
ing in oncogene-mediated mechanisms to control ma-
lignant potential [11,12].
A variety of biological characteristics, such as cell
cycle progression, cellular di¡erentiation, and malig-
nant transformation are regulated through a mecha-
nism of reversible protein phosphorylation carried
out by various protein kinases, some of which are
products of oncogenes and cell division control genes
[1,3]. These observations have led to the concept that
major biological events are manipulated by an elab-
orate network of interacting protein kinase pathways
[13]. In keeping with this concept is the observation
that the R2 protein of ribonucleotide reductase, a
rate-limiting protein in DNA synthesis [4], is phos-
phorylated by the protein kinase cell cycle regulators,
p34cdc2 and CDK2 [14]. In the present study, we
demonstrated that this phosphorylation event occurs
at a serine residue within 20 amino acids of the N-
terminal end of the R2 protein.
2. Materials and methods
2.1. Materials
[Q-32P]ATP (6000 Ci/mmol) was obtained from
Amersham (Oakville, Ont.). [14C]CDP (380 mCi/
mmol) was obtained from Moravek Biochemicals
(Brea, CA). Endoproteinase Asp-N was obtained
from Boehringer Mannheim (Laval, Que.). Oligonu-
cleotide primers were synthesized by Canadian Life
Technologies (Burlington, Ont.). Circumvent Ther-
mal cycle sequencing reagents were obtained from
New England Biolabs (Mississauga, Ont.). Peptides
were prepared on a peptide synthesizer (Model 431A,
Applied Biosystem). The p34cdc2 protein kinase was
highly puri¢ed from nocodazole-arrested human Jur-
kat T cells using 15^40% ammonium sulfate fraction-
ation followed by gel ¢ltration on Sephacryl
S-300HR (Pharmacia, Baie d’Urfe, Que.), and then
by ion exchange on DEAE-Sephacel (Pharmacia),
Econo Q (Bio-Rad, Mississauga, Ont.), and ¢nally
Econo S (Bio-Rad) [15]. P34cdc2 was monitored by
assaying kinase activity with a synthetic peptide sub-
strate (Gln-Leu-Gln-Leu-Gln-Ala-Ala-Ser-Asn-Phe-
Lys-Ser-Pro-Val-Lys-Thr-Ile-Arg) as previously de-
scribed [16]. The presence of p34cdc2 kinase in active
fractions was con¢rmed on immunoblots developed
with antibodies against a C-terminal peptide of
p34cdc2 kinase [16]. The puri¢ed material had a spe-
ci¢c activity of 0.33 Wmol/min/mg when assayed at
30‡C using histone H1 (Boehringer Mannheim) as
substrate. This preparation exhibited no activity to-
wards a synthetic peptide substrate of casein kinase
II (Arg-Arg-Arg-Asp-Asp-Asp-Ser-Asp-Asp-Asp), or
a synthetic peptide (Arg-Arg-Leu-Ser-Ser-Leu-Arg-
Ala) that is based on phosphorylation sites on ribo-
somal protein S6, that can be phosphorylated in vi-
tro by a number of protein kinases (including cAMP-
dependent protein kinase, protein kinase C, as well
as growth factor-activated protein kinases) [17,18].
Puri¢ed active p34cdc2 protein kinases were also ob-
tained from Upstate Biotechnology (Lake Placid,
NY), Santa Cruz Biotechnology (Santa Cruz, CA)
and New England Biolabs. Thin layer chromatogra-
phy (TLC) plates for phosphopeptide mapping were
purchased from Merck (Darmstadt, Germany). Anti-
R2 antiserum was obtained from New Zealand rab-
bits immunized with recombinant mouse R2 protein
BBAMCR 14387 5-1-99
A.K. Chan et al. / Biochimica et Biophysica Acta 1448 (1999) 363^371364
[14,19]. The large subunit of ribonucleotide reductase
(R1) used in enzyme activity assays was kindly pro-
vided by Dr. Harvey Rubin [20].
2.2. Construction of mutated R2 cDNA
A site-directed mutation was introduced into the
mouse R2 cDNA using the inverse PCR method as
described by Helmsley et al. [21]. Two oligonucleo-
tide primers which are complementary to the two
strands of the circular pET-M2 plasmid [19,22]
were synthesized. The 5P ends of the two primers
hybridize to adjacent nucleotides on the opposite
strands of the circular plasmid. The 3P ends prime
the synthesis of new DNA in the opposite directions
on the circular plasmid. Oligonucleotide primers
were synthesized with mutated sequences that could
generate a mutated R2 protein in which the serine-20
residue was substituted with either an alanine or a
threonine or an aspartic acid. Each of these primers
was combined with the primer that hybridized and
extended the opposite strand of the plasmid in a
PCR reaction (5P-TGCTGCTGGTCAGCGATGG-
T). The sequence of the oligonucleotide primer
used for generating the R2-Ala cDNA was 5P-GC-
TGCATTGGCGCCGCTGAAGCG. It contained a
Fig. 1. Synthetic peptides as substrates for p34cdc2 protein ki-
nase. Three synthetic peptides corresponding to amino acid resi-
dues 13^28 of the R2 protein were evaluated as substrates for
p34cdc2 kinase. (A) The serine peptide contains the wild type
amino acid sequence and was phosphorylated by p34cdc2 kinase.
(B) In the alanine peptide, the putative phosphorylation site at
serine-20 was substituted with an alanine residue, and the pep-
tide was not phosphorylated by p34cdc2 kinase. (C) The threo-
nine peptide was phosphorylated as e⁄ciently as the wild type
sequence. The phosphorylated peptides were analyzed by as-
cending chromatography and detected by autoradiography. The
phosphorylated peptides are marked by arrows.
Fig. 2. Phosphopeptide maps of phosphorylated recombinant R2 protein and a synthetic peptide containing the putative phosphoryla-
tion site. Puri¢ed recombinant R2 protein and the synthetic peptide were phosphorylated in vitro with puri¢ed p34cdc2 kinase, and
then digested exhaustively with Asp-N endoproteinase. Phosphopeptides were analyzed by electrophoresis (horizontal dimension, 3ve
electrode on the right side) and ascending chromatography (vertical dimension). Phosphopeptide mapping analysis was performed on
the following samples: (A) Asp-N treated synthetic peptide corresponding to the Asp-N digested fragment (amino acid residues 13^
28) of the R2 protein, which contains the serine-20 residue, (B) Asp-N digested recombinant R2 protein, and (C) a mixture of both
Asp-N digested peptide and Asp-N digested R2 protein. Phosphopeptides were detected by autoradiography. The origins are marked
with arrows.
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transversion mutation (TCG to GCG). The nucleo-
tide sequence of the primer used for generating the
R2-Thr cDNA was 5P-GCTGCAGTTGACGCCGC-
TGAAGCG. The nucleotide sequence of the primer
used for generating the R2-Asp cDNA was 5P-G-
CTGCAGTTGGAGCCGCTGAAGCG. The PCR
ampli¢cation was carried out with a Perkin-Elmer
Geneamp PCR system 9600 thermocycler in the
presence of the four deoxynucleotides (25 WM),
80 pmoles of the two primers, 10 ng of template
DNA, 50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-
HCl, pH 9.0 and 1 unit of Taq polymerase.
2.3. Expression and puri¢cation of recombinant
R2 protein
Mouse recombinant R2 protein was prepared from
bacteria containing the plasmid pETM2 according to
the method of Mann et al. [19], as we have described
previously [14]. No endogenous R2 kinase activities
were detected when the partially puri¢ed R2 prepa-
ration was treated with kinase assay bu¡er described
above.
2.4. Phosphorylation of recombinant R2 proteins and
peptides in vitro by puri¢ed p34cdc2
In vitro phosphorylation assays using wild type
and mutated R2 proteins, and synthetic R2 peptide
as substrates were carried out according to Haystead
et al. [23]. Typically, 5 units of puri¢ed p34cdc2 kinase
and 5 Wg of R2 or 20 nmoles of peptide were mixed
in the presence of [Q-32P]ATP and incubated at 30‡C
for 5 min. One unit of enzyme activity is the amount
of protein that will transfer 1 pmole of phosphate
from [Q-32P]ATP to histone H1 substrate per minute.
The R2 protein samples were analyzed on SDS-
PAGE and then detected by autoradiography. The
peptide samples were analyzed by ascending chroma-
tography on TLC plates and then detected by auto-
radiography [14].
2.5. Proteolytic digestion of R2 protein and peptide
Proteins were extracted from dried polyacrylamide
gels into bu¡er containing 50 mM NH4HCO3, pH
7.8, 0.1% SDS, and 1% mercaptoethanol as previ-
ously described [24,25]. Peptides were extracted
from the chromatographic resin into bu¡er contain-
ing 15% acetic acid and 5% formic acid, pH 1.9.
Recovered protein and peptide were treated with per-
formic acid, and digested with 2 units of Asp-N en-
doproteinase for 18 h at 37‡C. Digested products
were analyzed by a two-dimensional phosphopeptide
mapping procedure.
2.6. Two-dimensional phosphopeptide mapping and
phosphoamino acid analysis
Peptides resulting from Asp-N digestion were spot-
ted onto 10U10 cm cellulose TLC plates and sub-
jected to electrophoresis at 1000 V for approx. 20 min
in pH 1.9 bu¡er (15% acetic acid, 5% formic acid),
followed by ascending chromatography in solvent
that contained isobutyric acid, pyridine, acetic acid,
butanol, and water in a ratio of 65:5:3:2:29, respec-
tively [16,26]. Phosphopeptides were visualized by
autoradiography [14]. For phosphoamino acid anal-
ysis, the phosphopeptide was recovered from the
TLC plate and partial acid hydrolysis of the phos-
phopeptide was carried out in the presence of HCl at
110‡C for 1 h as previously described [14]. The acid
hydrolyzed product containing the phosphoamino
acids was mixed with phosphoamino acid standard
and analyzed by two-dimensional electrophoresis.
The phosphoamino acid standards were stained
with ninhydrin. The radioactive signals were detected
by storage phosphor screen (Molecular Dynamics).
2.7. DNA sequencing
The CircumVent DNA sequencing reagent kit
(New England Biolabs, Mississauga) was used to
screen for and con¢rm the mutated DNA sequences
of newly generated R2 cDNA clones. The PCR gen-
erated sequencing product was analyzed on urea pol-
yacrylamide gel and the labeled DNA was detected
by autoradiography. DNA sequences were also ob-
tained using the ABI Prism Big Dye terminator cycle
sequencing ready reaction kit and the ABI 310 Ge-
netic Analyzer (Perkin-Elmer, Foster City, CA).
2.8. Ribonucleotide reductase enzyme activity assay
Ribonucleotide reductase activity was estimated
using radioactively labeled cytidine 5P-diphosphate
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(14C-CDP) as substrate. Puri¢ed recombinant R2
proteins (approx. 1^4 Wg) were combined with puri-
¢ed recombinant R1 protein (3 Wg) and incubated for
20 min at 37‡C in the presence of 50 WM [14C]CDP,
6 mM dithiothreitol, 4 mM magnesium acetate and
2 mM ATP in a ¢nal volume of 80 Wl. The reaction
was terminated by boiling and then treated with Cro-
talus atrox snake venom dissolved in 0.1 M HEPES
(pH 8.0) bu¡er, containing 10 mM MgCl2. The re-
action product, deoxycytidine, was separated from
the cytidine compounds on Dowex-1-borate resin
columns [5,27,28].
3. Results and discussion
3.1. Synthetic peptides as a substrate for
p34cdc2 kinase
Evidence from previous studies indicated that the
ribonucleotide reductase R2 subunit was phosphoryl-
ated in vivo and the phosphorylated amino acid was
a serine. Phosphopeptide maps of recombinant R2
protein phosphorylated in vitro by p34cdc2 and
CDK2 kinases were identical to that of the native
R2 protein [14]. Analysis of the amino acid sequence
of the R2 protein revealed a sequence at serine-20
(Ser-Pro-Leu-Lys-Arg) which matched the consensus
sequence for p34cdc2 and CDK2 kinases [14]. To test
the hypothesis that serine-20 is the major site of
phosphorylation, we prepared three synthetic pepti-
des that contained the amino acid sequence between
Asp-13 and Ala-28 of the R2 protein. One of the
peptides (serine peptide) contained the wild type
sequence (Asp-Gln-Gln-Gln-Leu-Gln-Leu-Ser-Pro-
Leu-Lys-Arg-Leu-Thr-Leu-Ala), and the other two
peptides (alanine peptide and threonine peptide) con-
tained a mutation in which an alanine or a threonine
was substituted for the serine-20 residue. These three
peptides were tested for their suitability as a sub-
strate for p34cdc2 kinase. The kinase assay reaction
products were analyzed by TLC, and phosphorylated
peptides were detected by autoradiography. The ser-
ine peptide and threonine peptide were shown to be
readily phosphorylated by p34cdc2 protein kinase at a
rate of approx. 0.17 pmole of ATP transferred per
minute under in vitro kinase reaction conditions.
However, no phosphorylation of the alanine peptide
was detected (Fig. 1). The lack of phosphorylation in
the alanine peptide indicates that other residues in
the peptide are not suitable phosphorylation sites
for p34cdc2 kinase. These include the threonine resi-
due that is located near the carboxyl end of the pep-
tide, which corresponds to threonine-26 in the R2
protein. It appears that p34cdc2 kinase phosphoryla-
tion is speci¢c for serine or threonine residues which
are located within the consensus sequence: Ser/Thr-
Pro-Leu-Lys-Arg. This result suggests that the serine
residue on the serine peptide is the site of phospho-
rylation.
3.2. Phosphopeptide analysis of recombinant
R2 protein and synthetic peptide
The recombinant R2 protein and the synthetic ser-
ine peptide were phosphorylated in vitro by puri¢ed
p34cdc2 kinase and then digested with Asp-N endo-
proteinase. The digestion products were analyzed by
electrophoresis and ascending chromatography. We
attempted to con¢rm the identity of the phosphoryl-
ation site on the R2 protein by comparing the R2
phosphopeptide map to that of a synthetic peptide of
the same sequence. The serine peptide is identical to
the predicted peptide fragment of Asp-N digested R2
protein, which contains the putative phosphorylation
site (serine-20). Four distinct spots of varying inten-
sities were observed on the phosphopeptide map of
the serine peptide (Fig. 2A). The most prominent
spot contained about 80% of the total radioactivity
and the other three minor spots each contained be-
tween 5 and 10% of the radioactivity. Since this sam-
ple is a puri¢ed synthetic peptide and does not con-
tain an Asp-N cleavage site, it is likely that the major
spot is the phosphorylated serine peptide, and the
minor spots probably represent small quantities of
alternative digestion products. The phosphopeptide
map of recombinant R2 protein showed four spots
with di¡erent intensities. The major spot contained
about 75% of the total radioactive signal and the
other three minor spots which migrated to close
proximities of the major spot, each contained be-
tween 5 and 10% of the signal (Fig. 2B). Previous
studies, including R2 amino acid sequence analysis,
predicted only one probable p34cdc2 kinase phos-
phorylation site, at serine residue 20 [14]. Although
the identity of each of the spots in Fig. 2B was not
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established de¢nitively, it is highly likely that the
major phosphopeptide spot contained the phos-
phorylated serine-20 residue. The other three minor
spots probably represent either alternative digestion
products or alternative phosphorylation sites which
are phosphorylated with lower e⁄ciency. To directly
compare the phosphopeptide maps of the phos-
phorylated peptide and recombinant R2 protein,
equal amounts of each sample (based on cpm) were
combined and subjected to two-dimensional analysis
under the same conditions. Co-migration of the two
major spots suggests that the two phosphopeptides
are identical. Phosphopeptide analysis of the mixed
sample showed four spots and about 80% of the
radioactive signal was associated with one major
spot (Fig. 2C). The major spot from each sample
appeared to have co-migrated indicating that the
synthetic phosphopeptide and the major phospho-
peptide of Asp-N digested R2 were identical. Since
the only p34cdc2 consensus phosphorylation site in
the synthetic peptide is at serine-20, these results fur-
ther suggest that the major phosphorylation site on
the R2 protein occurs at the serine-20 residue.
3.3. In vitro phosphorylation of wild type and mutated
recombinant R2 protein
To further test the hypothesis that serine-20 is the
primary phosphorylated residue on R2 protein, we
have generated three recombinant R2 proteins (R2-
Thr, R2-Asp and R2-Ala) in which the serine-20 res-
idue was replaced by either a threonine or an as-
partic acid or an alanine residue respectively. This
was accomplished by introducing a site-speci¢c mu-
tation into the R2 cDNA of the expression plasmid
pET-M2 by inverse PCR. The wild type (R2-WT)
and mutated (R2-Thr and R2-Asp) recombinant R2
proteins were used as substrates for puri¢ed p34cdc2
Fig. 4. Phosphoamino acid analysis of mutated R2-Thr protein.
Puri¢ed recombinant R2-Thr protein was phosphorylated with
p34cdc2 kinase in the presence of [Q-32P]ATP followed by
TPCK-trypsin digestion and separation by two-dimensional
analysis. The isolated phosphopeptide was subjected to partial
acid hydrolysis with HCl and analyzed by two-dimensional elec-
trophoresis (¢rst dimension is vertical with 3ve electrode at
bottom). The three phosphoamino acid standards were stained
with ninhydrin and their positions were marked. The radioac-
tive signal was detected on storage phosphor screen and the sig-
nal was associated with only phosphothreonine.
Fig. 3. Phosphorylation of wild type and mutated recombinant
R2 proteins with p34cdc2 kinase. Wild type (R2-WT) and mu-
tated recombinant R2 proteins (R2-Thr, R2-Asp) were puri¢ed
from bacterial cells, and treated with p34cdc2 kinase in the pres-
ence of [Q-32P]ATP. The phosphorylated products were analyzed
on a 12% SDS-PAGE gel and phosphorylated proteins were de-
tected by autoradiography. (A) The polyacrylamide gel was
stained with Coomassie blue R to show the quantity of protein
contained in each of the R2-WT, R2-Thr and R2-Asp samples.
(B) Autoradiogram of the same polyacrylamide gel indicated
that there was signi¢cant phosphorylation of R2-WT and R2-
Thr protein but not of the mutated R2-Asp protein.
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kinase in the presence of [Q-32P]ATP, and then ana-
lyzed on SDS-PAGE. The gel was stained with Coo-
massie blue R to determine the relative amounts of
R2 protein on the gel (Fig. 3A). The phosphorylated
R2 proteins were detected by autoradiography. The
R2-WT and R2-Thr were phosphorylated by p34cdc2
kinase, whereas under the same conditions no signi¢-
cant phosphorylation of R2-Asp was detected (Fig.
3B). Furthermore, the mutated recombinant R2
protein containing an alanine substitution was also
not phosphorylated by p34cdc2 kinase (data not
shown).
3.4. Phosphoamino acid analysis of recombinant
R2-Thr protein
We attempted to further establish that serine-20
was the major phosphorylation site in the R2 protein
by analyzing the phosphoamino acid contained in
the mutated R2-Thr protein. Previous phosphoamino
acid analysis of in vivo and in vitro labeled R2 pro-
tein demonstrated that R2 is exclusively phosphoryl-
ated on serine [14]. In the R2-Thr, the putative
phosphorylation site serine-20 was substituted with
a threonine residue. This threonine residue was ex-
pected to be a suitable substrate for p34cdc2 kinase as
suggested by the e⁄cient phosphorylation of the
threonine peptide (Fig. 1) and R2-Thr (Fig. 3). If
serine-20 was the major phosphorylation site in R2
protein, it would be expected that phosphothreonine
would be the predominant phosphoamino acid in the
R2-Thr protein. Recombinant R2-Thr was phos-
phorylated with p34cdc2 kinase and then digested
with TPCK-trypsin. Peptides were separated by
two-dimensional analysis and only one predominant
phosphopeptide spot containing over 95% of radio-
active signal was observed (data not shown). This
phosphopeptide was recovered for phosphoamino
acid analysis and the result showed that the radio-
active signal was associated with only phosphothreo-
nine (Fig. 4). The presence of phosphoserine and
phosphotyrosine was not detected. The phosphoami-
no acid in R2 protein changed from phosphoserine
to phosphothreonine when serine-20 was replaced
with a threonine residue. This result provides strong
support for the hypothesis that serine-20 is the major
phosphorylation site for p34cdc2 kinase and CDK2.
3.5. Comparison between ribonucleotide reductase
activities of wild type R2 and mutated R2 proteins
Ribonucleotide reductase activities were measured
by combining puri¢ed wild type or mutated R2 pro-
teins with puri¢ed recombinant R1 protein in the
presence of substrate (14C-CDP). The wild type and
the three mutated R2 proteins, when combined with
R1 protein, showed similar enzyme activities under
these experimental conditions (Fig. 5). It appears
that the enzymatic functions of these mutated R2
proteins are not signi¢cantly a¡ected by the muta-
tions, and the conformational changes caused by the
mutation are not substantial. This suggests that the
lack of phosphorylation in R2-Ala and R2-Asp by
p34cdc2 kinase is likely due to the absence of serine-20
rather than gross conformational changes that inter-
fere with phosphorylation.
3.6. Conclusions
The above results ¢rmly establish that a major
Fig. 5. Ribonucleotide reductase enzyme activity assay. Enzyme
activities of recombinant wild type and mutated R2 proteins
were measured using [14C]CDP as substrate and supplemented
with recombinant R1 subunit. Ribonucleotide reductase activity
is expressed as nmoles 14C-dCDP generated per mg protein per
hour. The activity values are averages of three determinations
and standard deviations are indicated.
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phosphorylation site on the ribonucleotide reductase
R2 protein occurs near the N-terminal end at serine-
20, which is located within the sequence Ser-Pro-Leu-
Lys-Arg-Leu. Furthermore, there is a basic residue in
the third position on the C-terminal side of the phos-
phorylated amino acid, a characteristic that has been
observed for many p34cdc2 phosphorylation sites. The
¢nding that p34cdc2 and CDK2 kinases phosphoryl-
ate the cell cycle regulated ribonucleotide reductase
R2 protein, which is rate-limiting for enzyme activity
and therefore DNA synthesis [4,14], is consistent
with previously described roles for these kinases as
regulators of cell cycle progression [1^3]. For exam-
ple, p34cdc2 is most active during mitosis where it
directly participates in the control of G2/M transi-
tions [2,3], and CDK2 is an essential component of
the regulatory process underlying G1/S transition
events [29,30]. The results of the study presented in
this report, which conclusively demonstrate the pre-
cise location of R2 phosphorylation, provide a basis
for further investigations into the exact function of
this R2 modi¢cation and its potential signi¢cance in
relation to cell cycle events. One prediction, that pro-
tein phosphorylation may signi¢cantly alter overall
enzyme activity, was tested. We showed, however,
that mutations to the serine-20 residue do not signi¢-
cantly alter enzyme activity when assayed in vitro.
This does not, of course, rule out the possibility
that ribonucleotide reductase activity and its regula-
tion may be sensitive to R2 serine-20 phosphoryla-
tion status when the enzyme is functioning in its in
vivo environment. Other possible roles for serine-20
phosphorylation include the regulation of R2 protein
turnover, through for example phosphorylation regu-
lated ubiquitination mechanisms that lead to ubiqui-
tin dependent degradation, or serine-20 phosphoryl-
ation may modify cellular localization of the R2
subunit and sites of enzyme activity. It is also worth
noting that overexpression of the R2 protein has
been shown to modify the malignant characteristics
of tumor cells and the activity of the mitogen-acti-
vated protein kinase pathway [11,12]. This raises the
possibility that the R2 protein is capable of interact-
ing with other proteins in the cell in addition to the
R1 subunit of ribonucleotide reductase. R2 phos-
phorylation may in£uence these protein-protein in-
teractions. Studies are underway to test these possi-
bilities.
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